Neurologic Effects of SARS-CoV-2 Transmitted among Dogs
Dong-Hwi Kim
1, Da-Yoon Kim
1, Kyu-Sung Kim
1, Sang-Hoon Han, Hyeon-Jeong Go, Jae-Hyeong Kim, Kyu-Beom Lim, Dong-Hun Lee, Joong-Bok Lee, Seung-Yong Park, Chang-Seon Song, Sang-Won Lee, Yang-Kyu Choi, Yeun-Kyung Shin, Oh-Kyu Kwon, Do-Geun Kim
, and In-Soo Choi
Author affiliations: Konkuk University, Seoul, South Korea (D.-H. Kim, D.-Y. Kim, S.-H. Han, H.-J. Go, J.-H. Kim, K.-B. Lim, D.-H. Lee, J.-B. Lee, S.-Y. Park, C.-S. Song, S.-W. Lee, Y.-K. Choi, I.-S. Choi); Korea Brain Research Institute, Daegu, South Korea (K.-S. Kim, D.-G. Kim); Daegu Gyeongbuk Institute of Science and Technology, Daegu (K.-S. Kim, D.-G. Kim); Animal and Plant Quarantine Agency, Gimcheon, South Korea (Y.-K. Shin, O.-K. Kwon); Konkuk University Zoonotic Diseases Research Center, Seoul (D.-H. Lee, J.-B. Lee, S.-Y. Park, C.-S. Song, S.-W. Lee, I.-S. Choi); KU Center for Animal Blood Medical Science, Seoul (I.-S. Choi)
Main Article
Figure 1
Figure 1. Schematic diagram representing susceptibility to SARS-CoV-2 infection in the lungs and brain of animals with potential for human transmission and homology of ACE2 amino acid sequences in study of the neurologic effects of SARS-CoV-2. *Number of mutations among the key 20 residues involved in interacting with the SARS-CoV-2 RBD. ACE2, angiotensin-converting enzyme 2; RBD, receptor-binding domain.
Main Article
Page created: September 18, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.